Akero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH
January 24, 2025 16:05 ET | Source: Akero Therapeutics Inc. Investor webcast…
Akero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH
January 24, 2025 16:05 ET | Source: Akero Therapeutics Inc. Investor webcast…
Akero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH
January 24, 2025 16:05 ET | Source: Akero Therapeutics Inc. Investor webcast…
Akero Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 07, 2025 07:00 ET | Source: Akero Therapeutics Inc. SOUTH SAN…